Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

AMILORIDE ROSEMONT Oral solution (2017)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Amiloride Rosemont 5mg/5ml Oral Solution.

Qualitative and quantitative composition

Amiloride Hydrochloride BP 5.675mg equivalent to anhydrous Amiloride Hydrochloride 5mg.

Pharmaceutical form

Solution for oral administration.

Therapeutic indications

Potassium conserving agent; diuretic. Although Amiloride Hydrochloride may be used alone, its principal indication is as concurrent therapy with thiazides or more potent diuretics to conserve potassium ...

Posology and method of administration

Adults Amiloride Hydrochloride alone. The usual initial dosage is 10mg (as a single dose or 5mg twice a day). The total daily dose should not exceed 20mg (20ml) a day. After diuresis has been achieved, ...

Contraindications

Hyperkalaemia (plasma potassium over 5.5mmol/l) other potassium-conserving agents or potassium supplements (see Precautions); Addisons disease; anuria; acute renal failure, severe progressive renal disease, ...

Special warnings and precautions for use

Diabetes Mellitus To minimise the risk of hyperkalaemia in known or suspected diabetic patients, the status of renal function should be determined before initiating therapy. Amiloride Hydrochloride should ...

Interaction with other medicinal products and other forms of interaction

Lithium should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. When combined with thiazide diuretics, Amiloride can act synergistically with ...

Pregnancy and lactation

Because clinical experience is limited, Amiloride Hydrochloride is not recommended for use during pregnancy. The routine use of diuretics in otherwise healthy pregnant women with or without mild oedema ...

Effects on ability to drive and use machines

None known.

Undesirable effects

Amiloride Hydrochloride is normally well tolerated, although minor side effects are reported relatively frequently. Except for hyperkalaemia, significant side effects are infrequent. Nausea, anorexia, ...

Overdose

No data are available; and it is not known whether the drug is dialysable. The most likely signs and symptoms are dehydration and electrolyte imbalance which should be treated by established methods. Therapy ...

Pharmacodynamic properties

Amiloride has mild diuretic and anti-hypertensive activity. It acts primarily in the distal tubule and does not require aldosterone for its action. Amiloride is a mild natriuretic which does not initiate ...

Pharmacokinetic properties

Amiloride is incompletely absorbed from the gastro-intestinal tract; only about 50% is recovered unchanged in the urine following an oral dose. The drug is not metabolised and can, therefore, be useful ...

Preclinical safety data

None stated.

List of excipients

Citric Acid Monohydrate Ph Eur Methyl Hydroxybenzoate Ph Eur Propyl Hydroxybenzoate Ph Eur Propylene Glycol Ph Eur Vanillin Ph Eur Compound Orange Spirit BP Liquid Maltitol Ph Eur Purified Water Ph Eur ...

Incompatibilities

None known.

Shelf life

Shelf life in marketed pack 12 months.

Special precautions for storage

Store at or below 25 °C, out of reach of children.

Nature and contents of container

Glass (Type III) amber bottle, with capacity of 150ml. Closures: HDPE EPE wadded, tamper evident, child resistant.

Special precautions for disposal and other handling

None stated.

Marketing authorization holder

Rosemont Pharmaceuticals Ltd, Rosemont House, Yorkdale Industrial park, Braithwaite Street, Leeds, LS11 9XE

Marketing authorization number(s)

PL 00427/0091

Date of first authorization / renewal of the authorization

21 November 1995

Date of revision of the text

22/03/2017

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.